Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

被引:8
|
作者
Sanchez Hernandez, Alfredo [1 ]
Jose Juan, Oscar [2 ]
Vidal Martinez, Jose [3 ]
Blanco, Remei [4 ]
Macia, Sonia [5 ]
Esquerdo Galiana, Gaspar [6 ]
Aparisi Aparisi, Francisco [7 ]
Garde Noguera, Javier [8 ]
Catot, Silvia [9 ]
Losa Gaspa, Ferran [10 ]
Garcia-Pinon, Francisco [11 ]
机构
[1] Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12003, Spain
[2] Hosp Univ & Politecn La Fe, Med Oncol Serv, Valencia, Spain
[3] Hosp Arnau Vilanova, Serv Anal Clin, Valencia 46015, Spain
[4] Hosp Mutua de Terrassa, Med Oncol Serv, Barcelona 08221, Spain
[5] Hosp Gen Elda, Med Oncol Serv, Alicante 03600, Spain
[6] Clin Benidorm, Med Oncol Serv, Alicante 03501, Spain
[7] Hosp Virgen de los Lirios, Med Oncol Serv, Alicante 03804, Spain
[8] Hosp Arnau Vilanova, Med Oncol Serv, Valencia 46015, Spain
[9] Clin Althaia de Manresa, Med Oncol Serv, Barcelona 08243, Spain
[10] Hosp St Joan dEspi Moises Broggi, Med Oncol Serv, Barcelona 08970, Spain
[11] Hosp Prov Castellon, Fdn Comunidad Valenciana, Castellon de La Plana 12003, Spain
关键词
Circulating endothelial cell; NSCLC; Chemotherapy; PACLITAXEL-CARBOPLATIN; PERIPHERAL-BLOOD; SURROGATE MARKER; CLINICAL-VALUE; CANCER; ANGIOGENESIS; BEVACIZUMAB; PROGENITORS; CISPLATIN; SURVIVAL;
D O I
10.1007/s12094-014-1223-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). A prospective study was performed whose main objective was to study whether the numbers of CEC at baseline and prior to the second and third cycle of chemotherapy were response predictors. Sixty-nine patients received cisplatin plus pemetrexed, and peripheral blood samples were performed at baseline and after second and third cycle. Separation and CEC count were performed using inmunomagnetic separation (CellSearch). The CEC count in 4 mL of peripheral blood was obtained prior to the first, second, and third cycle of treatment. Baseline levels and evolution of CEC were correlated with response to treatment according to RECIST criteria after three cycles of treatment. Sixty-nine patients were included: 43 (64.2 %) received cisplatin/pemetrexed and 24 (35.8 %) carboplatin/pemetrexed. Range of baseline CEC: 8-965 (mean of 153 cel/4 mL). The results after 3 cycles were: 25 partial responses (36.2 %), 17 cases of stabilization of disease (24.6 %), 16 of progressive disease (23.2 %) and 11 non-evaluables (16 %). No significant relationship between the baseline CEC count and response was found (p value = 0.831). Increase > 50 % between the first and second cycle was correlated significantly with progression disease (p = 0.008). Patients who had a baseline CEC count greater than the mean (> 153 cells/4 mL) showed longer progression-free survival and global survival without statistical significance. In this homogeneous group of patients with NSCLC, there is no correlation between response to treatment and CEC baseline levels. The increase in CEC numbers after the first cycle could be a negative predictive factor.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 50 条
  • [41] Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice
    Zugazagoitia, J.
    Puente, J.
    Gonzalez-Larriba, J. L.
    Manzano, A.
    Sotelo, M.
    Hernandez, S.
    Sanz, J.
    Perez, P.
    Diaz-Rubio, E.
    ONCOLOGY, 2013, 84 (05) : 255 - 264
  • [42] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Yoh, Kiyotaka
    Goto, Koichi
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Abe, Tetsuya
    Tanaka, Hiroshi
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    MEDICAL ONCOLOGY, 2016, 33 (01) : 1 - 7
  • [43] The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma
    Chih-Jen Yang
    Ying-Ming Tsai
    Ming-Ju Tsai
    Hsu-Liang Chang
    Ming-Shyan Huang
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 199 - 205
  • [44] Does Pemetrexed/Platinum Fit All Patients with Non-Squamous Non-Small Cell Lung Cancer? A Retrospective Study of Clinical Factors and Outcomes
    Shimizu, Junichi
    Oya, Yuko
    Tanaka, Kosuke
    Yoshida, Tatsuya
    Horio, Yoshitsugu
    Yatabe, Yasushi
    Hida, Toyoaki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S541 - S541
  • [45] A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
    Verma, S.
    Chitikela, S.
    Singh, V.
    Khurana, S.
    Pushpam, D.
    Jain, D.
    Kumar, S.
    Gupta, Y.
    Malik, P. S.
    MEDICAL ONCOLOGY, 2023, 40 (07)
  • [46] Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety
    Cao, Hui
    Wei, Wei
    Lu, Yang
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (11) : 1775 - 1782
  • [47] Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients
    Yuan, Dong-mei
    Zhang, Qin
    Lv, Yan-ling
    Ma, Xing-qun
    Zhang, Yan
    Liu, Hong-bing
    Song, Yong
    TUMOR BIOLOGY, 2015, 36 (11) : 9031 - 9037
  • [48] Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
    Yaung, Stephanie J.
    Woestmann, Corinna
    Ju, Christine
    Ma, Xiaoju Max
    Gattam, Sandeep
    Zhou, Yiyong
    Xi, Liu
    Pal, Subrata
    Balasubramanyam, Aarthi
    Tikoo, Nalin
    Heussel, Claus Peter
    Thomas, Michael
    Kriegsmann, Mark
    Meister, Michael
    Schneider, Marc A.
    Herth, Felix J.
    Wehnl, Birgit
    Diehn, Maximilian
    Alizadeh, Ash A.
    Palma, John F.
    Muley, Thomas
    CANCERS, 2022, 14 (10)
  • [49] Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma
    Kuribayashi, Kozo
    Funaguchi, Norihiko
    Nakano, Takashi
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) : 528 - 534
  • [50] A PROSPECTIVE COHORT STUDY OF NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH BEVACIZUMAB
    Naoki, Katsuhiko
    Soejima, Kenzo
    Nagase, Seisuke
    Kanemura, Toshinori
    Ohhira, Tatsuo
    Takeda, Yuichiro
    Ikeda, Norihiko
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S868 - S868